Combined antihypertensive therapy in patients with arterial hypertension and coronary heart disease

Aim. To assess the potential of adding perindopril and indapamide CR (controlled release) to standard therapy, as a method for additional correction of cardiovascular risk factors (RFs) among patients with Stage 1-3 arterial hypertension (AH) of very high risk and coronary heart disease (CHD). Material and methods. In total, 44 patients (29 men, 15 women; age 45-80 years, mean age 56±10,7 years) with Stage 1-3 AH of very high risk and CHD were examined. At baseline and after 2, 4, and 16 weeks of the treatment, all participants underwent physical examination, office blood pressure (BP) measurement, standard laboratory tests, electrocardiography (ECG), Holter ECG monitoring, 24-hour BP monitoring, echocardiography (EchoCG), and arterial stiffness assessment. Results. All participants completed the study protocol, with no adverse effects during the treatment phase. In all patients with Stage 1-3 AH, target BP levels and improved 24-hour BP profile were achieved. In CHD patients, a reduction in the incidence of ischemic episodes and their duration was observed. There was a positive dynamics of arterial stiffness parameters. Conclusion. Perindopril and indapamide CR demonstrated good antihypertensive effectiveness, as well as cardioand vasoprotective activity in patients with very high-risk AH and CHD.